Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Sponsor: Novartis Pharmaceuticals
Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-EVS459 and the safety and imaging properties of \[68Ga\]Ga-EVS459 in patients aged ≥ 18 years with advanced high-grade serous ovarian cancer (OC) or locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (non-sq. NSCLC).
Official title: A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
4
Start Date
2024-09-08
Completion Date
2025-07-10
Last Updated
2026-06-23
Healthy Volunteers
No
Conditions
Interventions
[68Ga]Ga-EVS459
Radioligand imaging agent
[177Lu]Lu-EVS459
Radioligand therapy
Locations (1)
Novartis Investigative Site
Tel Aviv, Israel